alpha-MSH raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-11-25. Anything still debated is marked as such rather than presented as settled.
Outside the approved product, bremelanotide circulates as a research chemical sold by peptide vendors, often labelled PT-141. Such material is not manufactured under pharmaceutical quality standards, and independent testing has repeatedly found content that differs from the label. Analytical certificates supplied with a purchase are not strong evidence of purity because they are usually generated by the seller. Online discussion tends to blur the distinction between the approved drug and unregulated powder, which complicates interpretation of reported experiences.
PT-141 is the original development code for bremelanotide, a synthetic peptide first studied as a potential tanning and sexual-response agent in the 1990s. Researchers at a small American biotechnology firm designed it as a shortened analogue of melanotan II, which itself came from work on alpha-melanocyte-stimulating hormone. Early screening focused on pigmentation, but behavioural observations in animal models redirected attention toward sexual motivation. That shift made PT-141 one of the first melanocortin compounds investigated specifically for effects on desire rather than on skin colour.
Clinical development proceeded through two routes of administration. An intranasal formulation advanced first, but variable absorption and tolerability problems led to a switch to subcutaneous injection. The United States Food and Drug Administration approved the subcutaneous product in 2019 for hypoactive sexual desire disorder in premenopausal women. Marketing rights subsequently changed hands, and commercial availability has fluctuated since approval. Use in men, in postmenopausal women, and in combination with other agents remains outside the approved label.
Bremelanotide acts as an agonist at several melanocortin receptors, with the strongest reported activity at MC4R and measurable activity at MC1R and MC3R. Because MC4R is expressed in hypothalamic and limbic circuits, the proposed mechanism links receptor activation to modulation of central pathways involved in desire rather than to direct effects on peripheral genital tissue. The precise downstream steps remain incompletely characterized, and evidence for the involvement of specific neurotransmitters is suggestive rather than settled. Nausea and blood pressure elevation reported during trials are consistent with melanocortin signaling outside the intended target circuit.
Compared with melanotan II, bremelanotide is a smaller cyclic peptide with a more constrained backbone, which affects receptor selectivity and metabolic stability. Published descriptions give a plasma half-life on the order of a few hours after subcutaneous administration, with elimination through hepatic and renal routes and limited plasma protein binding. Central access is inferred from effects observed in animal models, although direct measurement in humans is limited. Handling and storage requirements follow from the peptide backbone, which is susceptible to hydrolysis and oxidation.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H68N14O10 | Free base; the drug product is formulated as an acetate salt |
| Molar mass | About 1025 g/mol | Calculated for the free base |
| Appearance | White to off-white lyophilized powder | Typical form of research-grade material |
| CAS Registry Number | 189691-06-3 | Common listing for the free base |
| Typical storage | -20 °C, desiccated, protected from light | Repeated freeze-thaw cycles are best avoided |
Approved use is narrow and jurisdiction-specific. In the United States, the injectable product is authorised for premenopausal women with acquired, generalised hypoactive sexual desire disorder, a diagnosis that requires documented distress. It is not approved for men, for postmenopausal women, or for use alongside hormonal contraceptives under the approved labelling. Outside regulated markets, the same peptide is frequently sold as a research chemical, where identity, purity, and sterility are not independently verified.
Bremelanotide is a synthetic cyclic heptapeptide developed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and appetite signalling. Its structure contains seven amino acid residues joined by a lactam bridge that closes the ring between two side chains. The molecular formula is C50H68N14O10 and the nominal molecular mass is near 1025 daltons. Much of the early laboratory literature refers to the same molecule by the development code PT-141.
Reported pharmacodynamic effects include transient rises in blood pressure and heart rate, flushing, nausea and headache, appearing soon after dosing and resolving within hours. These responses were dose-related in early studies and shaped the label's cardiovascular cautions and blood pressure monitoring advice. Gastrointestinal upset is the most frequent reason cited for discontinuation in trials. Whether the vascular signal attenuates with repeated use is not settled. Central effects on desire are described as emerging over weeks rather than immediately, which points to a cumulative rather than acute process.
The compound binds several melanocortin receptor subtypes rather than a single target, with the strongest functional activity reported at MC4R and measurable activity at MC1R, MC3R and MC5R. MC4R populations are dense in hypothalamic nuclei that integrate energy balance, autonomic tone and reproductive behaviour, which is the anatomical basis for the proposed pro-desire effect. Because binding is not subtype-selective, pigmentary and vascular effects accompany central activity. Improving subtype selectivity is an active area of analogue design. Direct causal mapping from receptor occupancy to reported desire change in humans is not fully established.
Johnson, the Battlegroup commander; Commander John Stufflebeem, leader of the VFA-103 F-14 squadron; Lt Barry McKibben, of the tactical unit; the Northrop Grumman E-2 Hawkeye airborne early warning aircraft, with Lt Scotty Bruce, Tactical Coordination officer, who watched for unidentified 'bogies' - the E-2 could take control of the fighter aircraft for the best interception; the E-6A Prowler had electronic jamming and could launch the AGM-88 HARM missile; Lt Chris Heath, Prowler pilot and Lt Darryl Leinhardt, electronic countermeasures officer; the HOTAS and forward-looking infrared systems of the Hornet; Commander Richard Kurrus aircraft handling officer; on landing, pilots attempt to catch the third of four wires; the Harold Wilson government of the UK decided to retire the UK's large strike carriers in 1966, which may have prompted the Falklands War, as the Argentinians would not have contemplated such an invasion otherwise; the French have the largest Navy in Europe, with its Foch carrier, and the new Dassault Rafale aircraft; the Invincible class light aircraft carriers were not recognised by the American military as full aircraft carriers; Captain Fabian Malbon, commanding officer of the Invincible; the Nimitz class was heavily protected against incoming attacks; Colonel John Schmidt of the Marine Ground Force; Denis Healey, Secretary State of Defence from 1964–70 and his cancellation of new British carriers in 1966; Admiral of the Fleet Terence Lewin; Admiral Edward H.
values of methane in internal isotopic equilibrium. As there are assumptions and approximations in calculations, the equilibrium distribution is only experimentally validated after the analysis of samples brought to thermodynamic equilibrium. Nickel and platinum catalysts have been used to equilibrate methane C-H bonds at various temperatures from 150 to 500 °C in laboratory. Currently, catalytic equilibration is also the practice to develop the reference material for clumped isotope analysis .
GCH Retail (Malaysia) Sdn Bhd, doing business as Giant Mall, is a hypermarket brand and retailer chain now mainly in Malaysia, Singapore and formerly Brunei, Cambodia, Indonesia and Vietnam. In 2016, Giant was the largest supermarket chain in Malaysia. Its parent company also operates Mercató, Cold Storage and TMC in Malaysia.
He is often shown to get along well with and prefer to be with his cousin Amber rather than his sister Haddie because Amber, given her own personal struggles, has a greater understanding of his condition. Max develops a mentor relationship with Hank Rizzoli, developing an interest in photography. Hank and Max connect as they both deal with the struggles of living with Asperger's Syndrome. Max finds success in photography and sees it as a future career. Max struggles with mainstream middle school. During an overnight school trip, other students bully him and Adam and Kristina need to take him home early. In response, Kristina creates a charter school, Chambers Academy, for students with learning difficulties who do not respond to general or special education settings. Max graduates from Chambers Academy in the series finale.
Sources: en.wikipedia.org
That December the headquarters of the 4th Ferrying Group of the Army Air Forces Air Transport Command shifted to the airport. The group was tasked with sending new aircraft overseas; pilots departed Memphis for South America and then flew over the South Atlantic Ocean to Africa. Personnel such as mechanics and engineers underwent training at the base and then traveled overseas. Chicago and Southern's repair facilities at the airport were used to repair military planes. Commercial air service continued, though it was limited. The ferrying group's postwar activities included moving planes off deactivated bases. For a period in 1946, Memphis served as headquarters for the Continental Division of the Air Transport Command, which oversaw the 4th Ferrying Group and ran scheduled flights for military personnel throughout the country. The ferrying group ceased operations in March 1947. City officials reached an agreement with the federal government in January 1949 to regain control of the airfield. Five trunk carriers flew to Memphis as of 1947, and two years later, a regional airline named Southern Airways launched operations with multi-stop service to Atlanta. The airport opened the first air-cargo terminal in the country in February 1958. The following year, passenger counts crossed one million. In August 1960, the city received its first scheduled jet flight; Delta Air Lines started using Convair 880s on its Chicago–Memphis–New Orleans route. The United States Supreme Court in Turner v. City of Memphis ordered the desegregation of the airport in 1962.
Another approach of making Sendai virus non-pathogenic included the short-term treatment of the virions with ultraviolet light. Such treatment causes a loss of the virus replication ability. However, even this replication-deficient virus can induce the cancer cells death and stimulate anti-tumor immunity. It can trigger extensive apoptosis of human glioblastoma cells in culture, and it can efficiently suppress the growth of these cells in model animals. The ultraviolet light treated virus can also kill human prostate cancer cells in culture by triggering their apoptosis and eradicate tumors that originated from these cells in immunodeficient model animals. Moreover, it can stimulate immunomodulated tumor regression of colon and kidney cancers in immunocompetent mice. Similar regressions caused by the replication-deficient Sendai virus have been observed in animals with transplanted melanoma tumors.
The amount of the unknown is determined from a standard curve. Nephelometry can be used to detect either antigen or antibody, but it is usually run with antibody as the reagent and the patient antigen as the unknown. In the Immunology Medical Lab, two types of tests can be run: "end point nephelometry" and "kinetic (rate) nephelometry". End point nephelometry tests are run by allowing the antibody/antigen reaction to run through to completion (until all of the present reagent antibodies and the present patient sample antigens that can aggregate have done so and no more complexes can form). However, the large particles will fall out of the solution and cause a false scatter reading, thus kinetic nephelometry was devised. In kinetic nephelometry, the rate of scatter is measured right after the reagent is added. As long as the reagent is constant the rate of change can be seen as directly related to the amount of antigen present.
== History == Proinsulin C-peptide was first described in 1967 in connection with the discovery of the insulin biosynthesis pathway. Isolation of bovin C-peptide, determination of sequence, preparation of human C-peptide were done in 1971. C-peptide serves as a linker between the A- and the B- chains of insulin and facilitates the efficient assembly, folding, and processing of insulin in the endoplasmic reticulum. Equimolar amounts of C-peptide and insulin are then stored in secretory granules of the pancreatic beta cells and both are eventually released to the portal circulation. Initially, the sole interest in C-peptide was as a marker of insulin secretion and has, as such, been of great value in furthering the understanding of the pathophysiology of type 1 and type 2 diabetes. The first documented use of the C-peptide test was in 1972. In the first decade of 21st century, C-peptide has been found to be a bioactive peptide in its own right, with effects on microvascular blood flow and tissue health.
== Physiological significance == ITGA1 is biologically significant because it functions as a key mediator of cell-extracellular matrix (ECM) communication. It's able to regulate interactions with ECM components (collagen and laminin) through the formation of the α1β1 integrin receptor. This influences cell adhesion, migration, survival, proliferation, tissue organization, and intracellular signaling, positioning ITGA1's significance as an important regulator of tissue maintenance, cellular adaptation, and responses to the surrounding microenvironment. The significance of ITGA1 is highly dependent on tissue type, cellular identity, and ECM composition. Although ITGA1 frequently promotes tumor progression in cancers such as PDAC, retinoblastoma, osteosarcoma, and glioma, its biological effects are not universally pro-tumorigenic. In different tissue types, ITGA1 has been observed to exhibit both tumor promoting and tumor suppressive functions. For example, ITGA1 has been reported to influence fibrosis-related pathways and normal tissue remodeling responses. Therefore the significance of ITGA1 depends on the specific biological context in which it is expressed. ITGA1 serves as a critical interface between the extracellular matrix (ECM) and intracellular signaling networks by mediating bidirectional communication between cells and their surrounding microenvironment.
Sources: en.wikipedia.org
PT-141 is a research code for bremelanotide, a cyclic peptide that activates melanocortin receptors. It was developed for sexual dysfunction and later approved under a brand name as a subcutaneous injection. The same code is widely used by suppliers selling non-pharmaceutical material.
Both are synthetic melanocortin agonists and share a similar peptide backbone, but they are distinct molecules with different receptor profiles. Melanotan II was never approved as a medicine, whereas bremelanotide was. Findings about one compound should not be transferred to the other without direct evidence.
It is typically distributed as a lyophilized powder in sealed vials, sometimes with a separate solvent. Purity statements usually originate from the supplier rather than an independent laboratory. Storage recommendations vary between vendors, which makes comparison across sources difficult.
Reported activity is highest at MC4R, with lower potency at MC1R and MC3R. The MC4R interaction is generally treated as the most relevant to its central effects. Selectivity is not absolute, and activity across the family is dose-dependent.